Cited by 91Obsessive-Compulsive Spectrum DisordersStuttering Research and TreatmentNeurological disorders and treatments

Recent advances in Tourette syndrome

Open access
Bloch, Michael, State, Matthew, Pittenger, Christopher·2011·Current Opinion in Neurology

Abstract

PURPOSE OF REVIEW: This review considers the recent literature pertaining to the neurobiology, genetics and treatment of Tourette syndrome. RECENT FINDINGS: Over the last several years, both neuropathological and genetic findings have further focused attention on long-standing hypotheses regarding the role of the basal ganglia in causing tics and Tourette syndrome. Moreover, although the field awaits the results the first large-scale genetic studies, recent findings have already mirrored developments in the neuropsychiatric genetics literature more broadly, highlighting the value of the study of rare variation and the overlap of risks among seemingly disparate diagnostic categories. Finally, treatment studies have underscored the importance of cognitive-behavioral as well as pharmacological interventions for the treatment of tic disorders. SUMMARY: Recent findings have led to novel, testable hypotheses regarding the molecular and cellular mechanisms underlying Tourette syndrome. These, in turn, have begun to provide new avenues to conceptualizing treatment strategies. Although the development of additional medication options is a pressing need, recent data has demonstrated both the safety and efficacy of nonpharmacological approaches.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/wco.0b013e328344648c

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Administration of dopamine antagonists such as risperidone and haloperidol is effective in suppressing tics in most TS patients.

    “Several clinical trials have shown that administration of dopamine antagonists, such as risperidone and haloperidol, are effective in suppressing tics in most patients (Bloch et al., 2011; Roessner et al., 2011).”

    From Response Inhibition and Interference Control in Obsessive–Compulsive Spectrum Disorders (2014) · cites this paper as Bloch et al., 2011

    The Recent Advances in Treatment section (page unavailable) reports that antipsychotics reduce tics, citing medium-to-large effects in several randomized, placebo-controlled trials. The Recent Advances in Neurobiology section identifies D2-blocking neuroleptics as effective TS medication. Our copy does not establish that risperidone and haloperidol specifically suppress tics in most patients. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Bloch, M., State, M., & Pittenger, C.
Affiliations
Yale University (US)
Corresponding author
  • Bloch, Michael
  • State, Matthew
  • Pittenger, Christopher
Venue
Current Opinion in Neurology
Published
2011-04
Volume
24
Issue
2
Pages
119-125
ISSN
1350-7540 (ISSN-L)
OpenAlex
W2153617058
Cited by
91
References
66
Citations by year
2026: 1 · 2024: 1 · 2022: 2 · 2021: 2 · 2020: 14 · 2019: 8 · 2018: 3 · 2017: 9 · 2016: 9 · 2015: 3 · 2014: 11 · 2013: 12 · 2012: 12
FWCI
1.91
Type
journal article
Language
en
Open access
Locations
  • Current Opinion in Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute of Mental Health (K08MH081190, R01MH091861, L40 MH075270, K23MH091240, R25MH077823)
  • National Institute of Neurological Disorders and Stroke (R01NS056276)
  • National Center for Research Resources (UL1RR024139)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
  • Social Sciences › Psychology › Clinical Psychology › Stuttering Research and Treatment
  • Health Sciences › Medicine › Neurology › Neurological disorders and treatments
Keywords
Tourette syndrome, tics, basal ganglia, neurobiology, rare variants, neuropsychiatric genetics, tic disorders, cognitive behavioral therapy, pharmacotherapy, non-pharmacological treatment
MeSH terms
Basal Ganglia, Tourette Syndrome, Histidine Decarboxylase, Humans, Tic Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review